Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24 17:16

Express News | The USA Biological Security Act was not included in the CR bill.

BreakingsDec 18 15:53

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 9 12:10

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 16:48

Hua Ling Pharmaceutical (02552.HK) has completed two drug studies.

Huale Pharmaceutical (02552.HK) announced in a press release that it had successfully completed the clinical study of the second-generation glucokinase activator (GKA) conducted in the usa at the Ninth China Pharma Innovation and Investment Conference earlier. The related clinical study is designed for once-daily oral administration, aiming to extend the drug's action time in the body through sustained-release technology, improve patient compliance, and prolong the stimulation of GLP-1 secretion in the intestine. In addition, Huale Pharmaceutical also announced on the same day that it had successfully completed the SENSITIZE study conducted in collaboration with the Chinese University of Hong Kong, which aims to improve β-cell function with multiple doses of rosiglitazone.

AASTOCKSDec 2 09:57

Express News | China's Leading Pharmaceutical announces the completion of two clinical studies.

BreakingsNov 30 18:02